| Title |
Adjuvant chemotherapy for stage II colon cancer: who really needs it
|
|---|---|
| Published in |
Cancer Management and Research, August 2018
|
| DOI | 10.2147/cmar.s160886 |
| Pubmed ID | |
| Authors |
Yan Yang, Yang Yang, Hui Yang, Fen Wang, Huihui Wang, Qi Chen, Ying Liu, Aiying Li, Quanan Zhang |
| Abstract |
Although there is evidence that failure to reach the baseline of 12-13 lymph nodes in resected specimens is related to poor prognosis of patients with stage II colon cancer, and may be a marker of adjuvant therapy, the use of these markers remains controversial. The objective of this study was to determine the advantage of chemotherapy treatment in patients with stage II colon cancer on the basis of the number of lymph nodes examined in radical surgery. Using monitoring, epidemiology, and final outcome Medicare database, we authenticated 9,651 patients aged ≥66 years diagnosed with resected stage II colon cancer from 1999 to 2004. Medical insurance claims determined the adoption of chemotherapy within 3 months after radical operation. The relation between patient/tumor characteristics (including the number of lymph nodes examined) and the use of adjuvant chemotherapy was tested using chi-squared test and multiple logistic regression. Multivariate Cox model was used to compare survival rates between the treatment and untreated groups. Most patients (54.8%) had only 1-12 lymph nodes examined, while only 41.6% of the patients had >12 lymph nodes examined. Overall, 20.9% of patients received adjuvant chemotherapy; there was no relationship between chemotherapy and the number of lymph nodes examined (P=0.984). The presence of 12 or fewer lymph nodes in surgical specimens was related to poor overall survival (OS; adjusted hazard ratio [HR] 1.31, 95% CI 1.21-1.41). Although adjuvant chemotherapy was related to our cohort improvement, its beneficial effects on OS (HR: 0.73; 95% CI: 0.64-0.83) and disease-free survival (HR: 0.71; 95% CI: 0.60-0.85) only existed in patients with 0-12 lymph nodes examined. The presence of 12 or fewer lymph nodes in surgical specimens is related to poor prognosis and survival benefit in adjuvant chemotherapy for stage II colon cancer patients. More attention should be paid to the implementation of recommendations for lymph node dissection to help identify patients who really benefit from adjuvant chemotherapy after colectomy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 3 | 21% |
| Student > Doctoral Student | 2 | 14% |
| Lecturer | 1 | 7% |
| Other | 1 | 7% |
| Researcher | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 6 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 43% |
| Nursing and Health Professions | 1 | 7% |
| Engineering | 1 | 7% |
| Unknown | 6 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 August 2018.
All research outputs
#15,542,971
of 23,099,576 outputs
Outputs from Cancer Management and Research
#731
of 2,019 outputs
Outputs of similar age
#210,107
of 331,041 outputs
Outputs of similar age from Cancer Management and Research
#36
of 89 outputs
Altmetric has tracked 23,099,576 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,019 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,041 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 89 others from the same source and published within six weeks on either side of this one. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.